rs1861494 — IFNG IFNG Interferon Gamma

Intronic IFNG variant that modulates interferon-gamma expression, with the T allele linked to elevated IFN-γ secretion, greater IBD disease severity, and altered susceptibility to tuberculosis and other immune-mediated conditions

See your personal result for IFNG

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IFNG rs1861494 — When the Immune Thermostat Runs Hot

Interferon-gamma is the immune system's master activator — the cytokine that tells macrophages to destroy intracellular pathogens, drives Th1 polarization11 Th1 polarization
Th1 cells are a subset of helper T cells that specialize in cell-mediated immunity against viruses and bacteria; their hallmark cytokine is interferon-gamma, and keeps chronic inflammatory responses calibrated against genuine threats. rs1861494 is an intronic polymorphism in IFNG that doesn't change the protein but influences how much interferon-gamma gets made. The T allele is associated with higher IFN-γ secretion — which sounds advantageous until the signal doesn't turn off, driving IBD flares, tissue damage, and a paradoxically complex relationship with infectious diseases.

The Mechanism

The IFNG gene sits on the minus strand of chromosome 12 (GRCh38 position 68,157,629). rs1861494 is located in intron 322 intron 3
Introns are non-coding segments of pre-mRNA that are spliced out before the message is translated into protein; intronic variants can alter RNA splicing, regulatory element binding, or epigenetic marks without changing amino acid sequence, 284 nucleotides downstream of exon 3 (c.366+284). Despite being non-coding, this position overlaps regulatory elements that control IFNG transcription.

The key finding from Gonsky et al. (2014) is that the T allele is associated with altered CpG methylation33 CpG methylation
DNA methylation at CpG dinucleotides is an epigenetic silencing mechanism; lower methylation at the IFNG promoter typically allows more transcription factor binding and higher IFN-γ output patterns at the IFNG promoter. T allele carriers show a profile associated with greater transcription factor access and higher IFN-γ protein secretion. This regulatory effect propagates from the intronic position through epigenetic remodeling — an intronic variant acting like a dial on cytokine output.

The Evidence

The most clinically informative study comes from inflammatory bowel disease. Gonsky et al. (Inflamm Bowel Dis, 2014, PMID 25171510)44 Gonsky et al. (Inflamm Bowel Dis, 2014, PMID 25171510) found that the T allele at rs1861494 associated with measurably higher IFN-γ protein secretion from intestinal tissue. In ulcerative colitis, T allele carriers showed higher levels of anti-neutrophil cytoplasmic autoantibodies (ANCA) and faster progression to colectomy. In Crohn's disease, they were more likely to develop the complicated stricturing/penetrating phenotype — the form requiring surgery. Critically, the study also showed that the methylation changes at the IFNG promoter correlate with T allele carriage, providing a mechanistic link between genotype and elevated cytokine output.

Tuberculosis data are more complex. In a Chinese Han population, Wu et al. (Cytokine, 2019, PMID 31310896)55 Wu et al. (Cytokine, 2019, PMID 31310896) found the C allele — not T — associated with TB susceptibility (OR 1.25, P=0.009), with a striking age effect: OR 2.40 in participants under 25. The same group, studying a Tibetan population (PMID 36524496)66 (PMID 36524496), found the opposite — CT genotype was protective relative to TT. An Indian cohort (Dhiman et al., Gene 2022, PMID 35248660)77 (Dhiman et al., Gene 2022, PMID 35248660) again reversed direction: T allele was the TB susceptibility allele (OR 2.18, P<0.001). This population heterogeneity is common for immune-response genes — the optimal IFN-γ level for clearing Mycobacterium tuberculosis differs by host genetic background, bacterial strain, and pathogen burden. The TB data should not be interpreted as a definitive risk signal in either direction; they illustrate that this variant modulates immune tone in a context-dependent way.

The most consistent finding across studies is the IBD-severity association: higher IFN-γ output in the gut correlates with more aggressive disease, suggesting the T allele tips the Th1/Th2 balance toward chronic mucosal inflammation in susceptible individuals.

Practical Implications

For TT homozygotes, the genetically elevated IFN-γ tone has two practical consequences. First, if you have or are at risk for IBD, this variant suggests your intestinal immune environment is already biased toward Th1-driven inflammation — a consideration for both monitoring and lifestyle decisions. Second, from a treatment standpoint, the IBD paper (PMID 25171510) noted that the T allele may predict better response to anti-TNF biologics88 anti-TNF biologics
Drugs like infliximab and adalimumab that block TNF-alpha, a cytokine that works alongside IFN-γ in the Th1 inflammatory cascade; IFN-γ high expressers may have greater TNF-dependent inflammation to suppress, which is clinically useful if treatment decisions arise.

For CT heterozygotes, IFN-γ output sits between the two homozygous states. Intermediate IFN-γ levels often represent the immunologically optimal range — sufficient for pathogen clearance without the inflammatory excess seen in TT carriers.

CC homozygotes, carrying two copies of the lower-expression allele, show a more restrained IFN-γ response. While this is associated with protection against IBD severity, some data suggest it may reduce Th1-mediated clearance of intracellular pathogens in certain population contexts.

Interactions

The most studied IFNG interaction involves the receptor gene IFNGR1, particularly its variants rs2234711 and rs3799488. These receptor variants alter IFN-γ signaling efficiency downstream of the cytokine itself. A high-producing genotype (TT at rs1861494) combined with impaired receptor signaling creates a decoupled system — more cytokine, less effect — while the combination of high production and normal receptor signaling amplifies both beneficial and harmful Th1 effects. rs1861493 (c.366+497) and rs2069718 (c.367-895) are neighboring IFNG intronic variants that have been studied in the same haplotype contexts; the rs1861493-rs1861494 TA haplotype has been associated with tuberculosis susceptibility in north Indian populations.

Genotype Interpretations

What each possible genotype means for this variant.

CC Low IFN-γ Expresser Beneficial

Lower interferon-gamma output associated with reduced inflammatory drive and IBD severity protection

You carry two copies of the C allele at rs1861494, the genotype associated with lower IFNG expression and reduced IFN-γ protein secretion. Studies of inflammatory bowel disease show that CC carriers are less likely to develop the severe UC phenotype requiring colectomy and less likely to progress to complicated Crohn's disease (stricturing/penetrating). About 10% of people of European descent and 7–14% of other ancestries share this CC genotype. Your interferon-gamma tone is biased toward Th2/regulatory rather than Th1-dominant immune responses.

CT Intermediate IFN-γ Expresser Intermediate

One T allele moderately elevates IFN-γ expression — intermediate inflammatory tone

The T allele at rs1861494 is associated with altered CpG methylation at the IFNG promoter and increased IFN-γ protein secretion. In CT heterozygotes, one chromosome carries the lower-expression C allele while the other carries the higher-expression T allele. The net effect is an IFN-γ output intermediate between the two homozygous states. For most people without IBD or autoimmune disease, this intermediate level is within normal immune range. The clinical relevance increases with additional inflammatory risk factors — other autoimmune risk variants, environmental triggers, or gut dysbiosis.

TT High IFN-γ Expresser High

Elevated interferon-gamma output linked to more severe IBD phenotypes and pronounced Th1 inflammatory bias

The mechanistic basis for the TT genotype's elevated IFN-γ output lies in altered CpG methylation at the IFNG promoter. Gonsky et al. (PMID 25171510) demonstrated that T allele carriage correlates with hypomethylation of specific CpG sites near the IFNG promoter, allowing greater transcription factor binding and higher cytokine gene expression. This epigenetic remodeling is visible in intestinal tissue, where TT carriers show measurably higher IFN-γ protein in secreted form.

In the gut, IFN-γ at high levels disrupts the epithelial barrier, promotes macrophage activation in the lamina propria, and sustains Th1-mediated inflammation — the core mechanism of Crohn's disease pathology. TT carriers with Crohn's disease were more likely to develop strictures and fistulas (penetrating disease), which require surgical intervention. In UC, TT genotype correlated with ANCA positivity and colectomy rates, both markers of aggressive, medically refractory disease.

The anti-TNF biologic response signal from Gonsky et al. is clinically relevant: patients with high IFN-γ secretion from this locus may have a favorable response to anti-TNF agents because high-IFN-γ IBD tends to have more TNF co-involvement in the Th1 inflammatory cascade. If anti-TNF therapy is being considered, your gastroenterologist should be aware of this genetic context.